Why is the IDT (ASX:IDT) share price halted today?

Trading in the pharmaceutical manufacturer is on hold pending an announcement.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The IDT Australia Limited (ASX: IDT) share price is on ice today after the company requested a trading halt.

Before it was put on hold, the IDT share price was trading at 48 cents apiece.

IDT is a Melbourne-based pharmaceutical company involved in manufacturing mRNA for use in COVID-19 vaccines.

a medical person in full protective clothing holds a tray of Covid-19 vaccinations amid a haze caused by cold and ice.

Image source: Getty Images

Why is the IDT share price halted?

IDT has been granted a trading halt pending an upcoming public announcement on mRNA vaccine production.

The company needs to consider its response to an announcement by the federal government on local mRNA manufacturing.

The company said it's not in a position to announce this to the market at present.

Early on Tuesday, the government revealed it has struck a deal with Moderna to build a new vaccine manufacturing facility in Victoria. At the time of writing, it's not clear if IDT will play any role in this deal.

IDT does not expect the trading halt to last more than two days and will make an announcement prior to this time.

What is the company working on?

As reported by Motley Fool Australia, IDT has reported it's successfully manufactured an mRNA drug product for use in a COVID-19 vaccine candidate.

On Monday, the company provided an update to investors on its mRNA manufacturing initiatives.

The company sees an unmet market need for commercial-scale manufacturing of mRNA.

IDT stated it wants to grow its mRNA facilities to become Australia's mRNA "manufacturing hub of excellence".

IDT share price snapshot

In the last 12 months, the IDT share price has sky rocketed 134% and has rallied 159% in the year to date.

Despite this, it's slipped 2% in the last month and 3% in the past week.

IDT has a market capitalisation of roughly $115 million based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Woman with long hair smiles for the camera.
Healthcare Shares

Why I'd buy CSL shares while sentiment is weak

The market no longer treats this ASX healthcare giant as flawless, and that may make the investment case more interesting.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Is this exciting healthcare stock a buy, hold or sell after rocketing 16% yesterday?

Can this soaring stock keep rising?

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 28% in a year, should I buy the dip on Resmed shares right now?

A leading analyst provides his outlook for the beaten-down ResMed share price.

Read more »

A businessman points to an arrow going up on a graph, indicating a share price rise for an ASX company.
Broker Notes

Up 1,277% in a year, why 4DMedical shares are tipped for more outsized gains

A leading analyst forecasts more outperformance from 4DMedical’s rocketing shares. But why?

Read more »

A person bounces another up high from a seesaw as the one in the air looks through a telescope into the future.
Healthcare Shares

Has the CSL share price finally bottomed out?

Is this beaten-down ASX healthcare giant finally turning a corner?

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Why everyone selling Cochlear shares right now could regret it in 3 years

Cochlear shares are down 65%. Here's why investors selling up right now could look back and wish they'd done the…

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Healthcare Shares

Here's what brokers tip for CSL shares over the next 12 months

The beaten-down biotech company's shares are still falling.

Read more »

three excited doctors with hands in the air
Healthcare Shares

Pro Medicus announces $16m US contract renewal

Pro Medicus secures a major US contract renewal, strengthening its US footprint and underlining continued client retention.

Read more »